OncoVAX® is an active specific immunotherapy (ASI) that uses a patient’s own tumor cells to prevent the return of cancer following surgery. This patient-specific vaccine is comprised of sterile, metabolically-active, irradiated, and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin ("BCG") bacteria as an adjuvant.
This is how OncoVAX® works: following surgical resection of a tumor, the cells are processed in Vaccinogen’s facility in the Netherlands. After processing the cells into an injectable vaccine, OncoVAX® is delivered under the patient’s skin in four doses over the first six months after surgery. The injections produce a delayed-type hypersensitivity (DTH) response which indicates the body’s own T-cells are responding to the unique tumor antigens.
In short, the vaccine teaches the body’s own immune system how to fight a cancer that it otherwise would not have recognized.
"We are excited about OncoVAX®'s potential for becoming the first patient-specific immunotherapy to prevent the recurrence of colon cancer."
“Our culture is fitting to the OncoVAX® opportunity. Accordingly, we are building a world-class team that is equal to this culture and moment.”
"You can't solve a heterogeneous problem with a homogeneous drug."
Vaccinogen's scientists, researchers and inventors are working diligently to bring new innovations to the field of cancer immunotherapy. With these innovations, our goal is to extend our previous OncoVAX® technology to treat new tumors and new patients, but also significantly advance the field of cancer immunology with novel first-in-class therapeutics.
For example, our team is currently in the process of refining our Oncavert™ therapeutic initiatives on several important fronts. Using our collection of in vivo data generated from cancer patients who have been immunized with OncoVAX®, we are working to develop pioneering new approaches to active cancer immunotherapy. Our objective is to create novel antibodies, novel peptides, and new therapeutic products that are safe and effective.
We believe we are uniquely positioned to develop and launch these new initiatives due to the wealth of information we have garnered from numerous cancer patients over the years. We believe meticulous collection and screening of immunologically relevant data and materials from individuals who have acquired anti-cancer immunity have proven, and will prove, extremely useful to discovering novel antibodies, novel peptides, and new therapeutic products.
Vaccinogen is in the initial phases of patenting the inventions it has conceived, including new inventions to create active anti-cancer vaccine products; new methods of discovering and making therapeutic products; new methods of eliciting immunogenic and prophylactic responses against recurrent disease in cancer survivors; and, moreover, new methods and therapeutic products for the prevention of cancer in normal individuals who have yet to demonstrate any recognizable neoplastic condition. In addition, we believe we have sophisticated intellectual property legal strategies in place to protect these new initiatives. In summary, the goal of these new products and methods is to train the human immune system to target and overcome the initiation of cancer in ways we believe have not been fully recognized or understood by the scientific community.